Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 79.10% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday, October 4th. Leerink Partners began coverage on Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Raymond James began coverage on Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 price objective on the stock. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Finally, B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.43.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $3.35 on Tuesday. The firm has a market capitalization of $235.96 million, a P/E ratio of -9.85 and a beta of 0.97. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00. The business’s 50-day simple moving average is $3.09 and its 200-day simple moving average is $2.89.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the previous year, the business earned ($0.07) earnings per share. On average, equities research analysts expect that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at $644,205.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Thomas Sciascia sold 18,660 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,355 shares of company stock worth $116,663 in the last three months. 24.37% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Logos Global Management LP lifted its holdings in shares of Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after buying an additional 600,000 shares during the period. Oppenheimer & Co. Inc. acquired a new position in Trevi Therapeutics in the 1st quarter worth about $208,000. Vanguard Group Inc. increased its position in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after purchasing an additional 60,249 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Trevi Therapeutics by 38.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after acquiring an additional 49,884 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in Trevi Therapeutics during the 1st quarter valued at approximately $47,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.